{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:49:12Z","timestamp":1792698552424,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["CroosRef Funder ID 009504"],"award-info":[{"award-number":["CroosRef Funder ID 009504"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>The increasing availability of disease-modifying therapies (DMTs) may provide more personalized treatment options for multiple sclerosis (MS) based on various factors, including patients\u2019 characteristics, prognostic indicators, comorbidities, and safety. In Italy, recent efforts focused on promoting interdisciplinary, patient-centered care and equitable access to optimized therapies, as reported in the <jats:italic>2023 Barometer of Multiple Sclerosis and Related Diseases<\/jats:italic> from the Italian Multiple Sclerosis Association. A key challenge is ensuring equitable access to homogeneous and personalized therapeutic strategies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods<\/jats:title>\n            <jats:p>Using a Delphi methodology, a panel of Italian neurologists with expertise in MS evaluated consensus on specific aspects of MS treatments, including personalized therapy, patient involvement in decision-making, treatment flexibility, self-management of therapies, perception of treatment efficacy and safety and therapeutic sequence management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 166 votes, 116 statements reached consensus (68% positive, 2% negative), representing 70% of the total, whereas 50 (30%) highlighted areas of non-consensus. The findings emphasize the central role of neurologists, the importance of personalized therapy, the inclusion of patients in therapeutic choices to enhance adherence and quality of life, and managing both quality of life and caregiver burden. Most high-efficacy disease-modifying therapies (HE DMTs), like cladribine and anti-CD20 therapies, recognized for their efficacy and convenience of administration, received positive consensus, emphasizing their perceived value in individualized treatment approaches.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This research highlights best practices and provides a roadmap for improving patient outcomes through tailored, well-communicated therapeutic strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00415-025-13173-2","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T10:00:45Z","timestamp":1748340045000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Personalized therapy in multiple sclerosis: an Italian Delphi consensus"],"prefix":"10.1007","volume":"272","author":[{"given":"Claudio","family":"Gasperini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Centonze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Lugaresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Trojano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-0479","authenticated-orcid":false,"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"issue":"1","key":"13173_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","volume":"4","author":"M Filippi","year":"2018","unstructured":"Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S et al (2018) Multiple sclerosis. Nat Rev Dis Prim 4(1):43. https:\/\/doi.org\/10.1038\/s41572-018-0041-4","journal-title":"Nat Rev Dis Prim"},{"issue":"10076","key":"13173_CR2","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","volume":"389","author":"G Comi","year":"2017","unstructured":"Comi G, Radaelli M, Soelberg SP (2017) Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet 389(10076):1347\u20131356. https:\/\/doi.org\/10.1016\/S0140-6736(16)32388-1","journal-title":"Lancet"},{"issue":"2","key":"13173_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40120-020-00212-5","volume":"9","author":"G Giovannoni","year":"2020","unstructured":"Giovannoni G, Lang S, Wolff R, Duffy S, Hyde R, Kinter E et al (2020) A systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis. Neurol Ther 9(2):359\u2013374. https:\/\/doi.org\/10.1007\/s40120-020-00212-5","journal-title":"Neurol Ther"},{"issue":"2","key":"13173_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D et al (2018) ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 24(2):96\u2013120. https:\/\/doi.org\/10.1177\/1352458517751049","journal-title":"Mult Scler"},{"issue":"17","key":"13173_CR5","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS et al (2018) Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 90(17):777\u2013788. https:\/\/doi.org\/10.1212\/WNL.0000000000005347","journal-title":"Neurology"},{"issue":"1","key":"13173_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ncl.2020.09.002","volume":"39","author":"C Goldschmidt","year":"2021","unstructured":"Goldschmidt C, McGinley MP (2021) Advances in the treatment of multiple sclerosis. Neurol Clin 39(1):21\u201333. https:\/\/doi.org\/10.1016\/j.ncl.2020.09.002","journal-title":"Neurol Clin"},{"key":"13173_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.106009","volume":"95","author":"D Ontaneda","year":"2020","unstructured":"Ontaneda D, Tallantyre EC, Raza PC, Planchon SM, Nakamura K, Miller D et al (2020) Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: the DELIVER-MS study protocol. Contemp Clin Trials 95:106009. https:\/\/doi.org\/10.1016\/j.cct.2020.106009","journal-title":"Contemp Clin Trials"},{"issue":"6","key":"13173_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2217\/cer-2020-0267","volume":"10","author":"IA Samjoo","year":"2021","unstructured":"Samjoo IA, Worthington E, Drudge C, Zhao M, Cameron C, Haring DA et al (2021) Efficacy classification of modern therapies in multiple sclerosis. J Comp Eff Res 10(6):495\u2013507. https:\/\/doi.org\/10.2217\/cer-2020-0267","journal-title":"J Comp Eff Res"},{"key":"13173_CR9","unstructured":"AISM (2023) AISM. Barometro della Sclerosi Multipla e patologie correlate-2023. Associazione Italiana Sclerosi Multipla (AISM). https:\/\/www.aism.it\/sites\/default\/files\/2023-10\/barometro_2023_web.pdf"},{"issue":"4","key":"13173_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","volume":"67","author":"IR Diamond","year":"2014","unstructured":"Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM et al (2014) Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol 67(4):401\u2013409. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.12.002","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"13173_CR11","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1177\/0269216317690685","volume":"31","author":"S Junger","year":"2017","unstructured":"Junger S, Payne SA, Brine J, Radbruch L, Brearley SG (2017) Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: Recommendations based on a methodological systematic review. Palliat Med 31(8):684\u2013706. https:\/\/doi.org\/10.1177\/0269216317690685","journal-title":"Palliat Med"},{"issue":"4","key":"13173_CR12","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","volume":"32","author":"F Hasson","year":"2000","unstructured":"Hasson F, Keeney S, McKenna H (2000) Research guidelines for the Delphi survey technique. J Adv Nurs 32(4):1008\u20131015","journal-title":"J Adv Nurs"},{"key":"13173_CR13","first-page":"10","volume":"12","author":"C-C Hsu","year":"2007","unstructured":"Hsu C-C, Sandford BA (2007) The Delphi technique: making sense of consensus. Pract Assess Res Eval 12:10","journal-title":"Pract Assess Res Eval"},{"issue":"1","key":"13173_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10072-018-3610-0","volume":"40","author":"M Trojano","year":"2019","unstructured":"Trojano M, Bergamaschi R, Amato MP, Comi G, Ghezzi A, Lepore V et al (2019) The Italian multiple sclerosis register. Neurol Sci 40(1):155\u2013165. https:\/\/doi.org\/10.1007\/s10072-018-3610-0","journal-title":"Neurol Sci"},{"key":"13173_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00166","volume":"7","author":"G Fasola","year":"2023","unstructured":"Fasola G, Barducci MC, Tozzi VD, Cavanna L, Cinieri S, Perrone F et al (2023) Implementation of precision oncology in the National Healthcare System: a statement proposal endorsed by Italian scientific societies. JCO Precis Oncol 7:e2300166. https:\/\/doi.org\/10.1200\/PO.23.00166","journal-title":"JCO Precis Oncol"},{"issue":"24","key":"13173_CR16","doi-asserted-by":"publisher","first-page":"13372","DOI":"10.3390\/ijerph182413372","volume":"18","author":"M Cascella","year":"2021","unstructured":"Cascella M, Miceli L, Cutugno F, Di Lorenzo G, Morabito A, Oriente A et al (2021) A Delphi consensus approach for the management of chronic pain during and after the COVID-19 era. Int J Environ Res Public Health 18(24):13372. https:\/\/doi.org\/10.3390\/ijerph182413372","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"13173_CR17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40122-023-00512-2","volume":"12","author":"F Occhigrossi","year":"2023","unstructured":"Occhigrossi F, Carpenedo R, Leoni MLG, Varrassi G, Chine E, Cascella M et al (2023) Delphi-based expert consensus statements for the management of percutaneous radiofrequency neurotomy in the treatment of lumbar facet joint syndrome. Pain Ther 12(3):863\u2013877. https:\/\/doi.org\/10.1007\/s40122-023-00512-2","journal-title":"Pain Ther"},{"key":"13173_CR18","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.2147\/JPR.S314206","volume":"14","author":"C Mattia","year":"2021","unstructured":"Mattia C, Luongo L, Innamorato M, Melis L, Sofia M, Zappi L et al (2021) An Italian expert consensus on the use of opioids for the management of chronic non-oncological pain in clinical practice: focus on buprenorphine. J Pain Res 14:3193\u20133206. https:\/\/doi.org\/10.2147\/JPR.S314206","journal-title":"J Pain Res"},{"issue":"1","key":"13173_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12874-020-0912-8","volume":"20","author":"T Lange","year":"2020","unstructured":"Lange T, Kopkow C, Lutzner J, Gunther KP, Gravius S, Scharf HP et al (2020) Comparison of different rating scales for the use in Delphi studies: different scales lead to different consensus and show different test-retest reliability. BMC Med Res Methodol 20(1):28. https:\/\/doi.org\/10.1186\/s12874-020-0912-8","journal-title":"BMC Med Res Methodol"},{"issue":"2 Suppl 76","key":"13173_CR20","first-page":"24","volume":"31","author":"C Coulter","year":"2013","unstructured":"Coulter C, Baron M, Pope JE (2013) A Delphi exercise and cluster analysis to aid in the development of potential classification criteria for systemic sclerosis using SSc experts and databases. Clin Exp Rheumatol 31(2 Suppl 76):24\u201330","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"13173_CR21","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/1352458519845107","volume":"26","author":"JR Falet","year":"2020","unstructured":"Falet JR, Deshmukh S, Al-Jassim A, Sigler G, Babinski M, Moore F (2020) The neurologist\u2019s role in disabling multiple sclerosis: a qualitative study of patient and care provider perspectives. Mult Scler 26(7):837\u2013842. https:\/\/doi.org\/10.1177\/1352458519845107","journal-title":"Mult Scler"},{"issue":"5","key":"13173_CR22","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41582-019-0170-8","volume":"15","author":"D Rotstein","year":"2019","unstructured":"Rotstein D, Montalban X (2019) Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol 15(5):287\u2013300. https:\/\/doi.org\/10.1038\/s41582-019-0170-8","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"13173_CR23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3390\/jpm11080791","volume":"11","author":"A Henschke","year":"2021","unstructured":"Henschke A, Desborough J, Parkinson A, Brunoro C, Fanning V, Lueck C et al (2021) Personalizing medicine and technologies to address the experiences and needs of people with multiple sclerosis. J Pers Med 11(8):791. https:\/\/doi.org\/10.3390\/jpm11080791","journal-title":"J Pers Med"},{"issue":"4","key":"13173_CR24","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.3390\/ijerph19042203","volume":"19","author":"A Koltuniuk","year":"2022","unstructured":"Koltuniuk A, Chojdak-Lukasiewicz J (2022) Adherence to therapy in patients with multiple sclerosis\u2014review. Int J Environ Res Public Health 19(4):2203. https:\/\/doi.org\/10.3390\/ijerph19042203","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"13173_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1177\/1352458519881558","volume":"26","author":"T Chitnis","year":"2020","unstructured":"Chitnis T, Prat A (2020) A roadmap to precision medicine for multiple sclerosis. Mult Scler 26(5):522\u2013532. https:\/\/doi.org\/10.1177\/1352458519881558","journal-title":"Mult Scler"},{"issue":"8","key":"13173_CR26","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41573-022-00477-5","volume":"21","author":"L Bierhansl","year":"2022","unstructured":"Bierhansl L, Hartung HP, Aktas O, Ruck T, Roden M, Meuth SG (2022) Thinking outside the box: non-canonical targets in multiple sclerosis. Nat Rev Drug Discov 21(8):578\u2013600. https:\/\/doi.org\/10.1038\/s41573-022-00477-5","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"13173_CR27","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Amato MP, Centonze D, Gallo P, Gasperini C, Inglese M et al (2022) Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol 269(10):5382\u20135394. https:\/\/doi.org\/10.1007\/s00415-022-11193-w","journal-title":"J Neurol"},{"key":"13173_CR28","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3389\/fneur.2020.00851","volume":"11","author":"M Magyari","year":"2020","unstructured":"Magyari M, Sorensen PS (2020) Comorbidity in multiple sclerosis. Front Neurol 11:851. https:\/\/doi.org\/10.3389\/fneur.2020.00851","journal-title":"Front Neurol"},{"issue":"6","key":"13173_CR29","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nrneurol.2017.33","volume":"13","author":"RA Marrie","year":"2017","unstructured":"Marrie RA (2017) Comorbidity in multiple sclerosis: implications for patient care. Nat Rev Neurol 13(6):375\u2013382. https:\/\/doi.org\/10.1038\/nrneurol.2017.33","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"13173_CR30","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200253","volume":"14","author":"EL Graham","year":"2024","unstructured":"Graham EL, Bove R, Costello K, Crayton H, Jacobs DA, Shah S et al (2024) Practical considerations for managing pregnancy in patients with multiple sclerosis: dispelling the myths. Neurol Clin Pract 14(2):e200253. https:\/\/doi.org\/10.1212\/CPJ.0000000000200253","journal-title":"Neurol Clin Pract"},{"issue":"4","key":"13173_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11940-021-00666-4","volume":"23","author":"KM Krysko","year":"2021","unstructured":"Krysko KM, Bove R, Dobson R, Jokubaitis V, Hellwig K (2021) Treatment of women with multiple sclerosis planning pregnancy. Curr Treat Options Neurol 23(4):11. https:\/\/doi.org\/10.1007\/s11940-021-00666-4","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"13173_CR32","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200349","volume":"12","author":"S Vukusic","year":"2025","unstructured":"Vukusic S, Bove R, Dobson R, McElrath T, Oreja-Guevara C, Pietrasanta C et al (2025) Pregnancy and infant outcomes in women with multiple sclerosis treated with ocrelizumab. Neurol Neuroimmunol Neuroinflamm 12(1):e200349. https:\/\/doi.org\/10.1212\/NXI.0000000000200349","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13173_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101137","volume":"48","author":"N Bast","year":"2025","unstructured":"Bast N, Dost-Kovalsky K, Haben S, Friedmann N, Witt L, Oganowski T et al (2025) Impact of disease-modifying therapies on pregnancy outcomes in multiple sclerosis: a prospective cohort study from the German multiple sclerosis and pregnancy registry. Lancet Reg Health Eur 48:101137. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101137","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"13173_CR34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/pn-2022-003426","volume":"23","author":"R Dobson","year":"2023","unstructured":"Dobson R, Rog D, Ovadia C, Murray K, Hughes S, Ford HL et al (2023) Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines. Pract Neurol 23(1):6\u201314. https:\/\/doi.org\/10.1136\/pn-2022-003426","journal-title":"Pract Neurol"},{"issue":"8","key":"13173_CR35","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s40263-022-00939-9","volume":"36","author":"S Faissner","year":"2022","unstructured":"Faissner S, Gold R (2022) Efficacy and safety of multiple sclerosis drugs approved since 2018 and future developments. CNS Drugs 36(8):803\u2013817. https:\/\/doi.org\/10.1007\/s40263-022-00939-9","journal-title":"CNS Drugs"},{"issue":"5","key":"13173_CR36","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1017\/cjn.2018.17","volume":"45","author":"MS Freedman","year":"2018","unstructured":"Freedman MS, Selchen D, Prat A, Giacomini PS (2018) Managing multiple sclerosis: treatment initiation, modification, and sequencing. Can J Neurol Sci 45(5):489\u2013503. https:\/\/doi.org\/10.1017\/cjn.2018.17","journal-title":"Can J Neurol Sci"},{"key":"13173_CR37","doi-asserted-by":"publisher","first-page":"204062232110630","DOI":"10.1177\/20406223211063032","volume":"13","author":"H Inojosa","year":"2022","unstructured":"Inojosa H, Proschmann U, Akgun K, Ziemssen T (2022) The need for a strategic therapeutic approach: multiple sclerosis in check. Ther Adv Chronic Dis 13:20406223211063030. https:\/\/doi.org\/10.1177\/20406223211063032","journal-title":"Ther Adv Chronic Dis"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13173-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13173-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13173-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T13:25:24Z","timestamp":1749907524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13173-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["13173"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13173-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Claudio Gasperini received honoraria for speaking and travel grants from Biogen, Merck, Novartis, Bristol Mayer, Roche, Viatris, Sanofi, Sandoz, Astra Zeneca and Almirall. Diego Centonze acted as an Advisory Board member and received honoraria for speaking or consultation fees from Alexion, Almirall, Amicus, Bayer, Biogen, BMS, Celgene, Chiesi, GW Pharmaceuticals, Horizon, Janssen, Lundbeck, Merck Serono, Novartis, Roche, Sandoz, Sanofi-Genzyme, Viatris, and Teva; he is also the Principal Investigator in clinical trials of Biogen, BMS, Merck Serono, Mitsubishi, Novartis, Roche, Sanofi-Genzyme, Actelion; his preclinical and clinical research was supported by grants from Bayer Schering, BMS, Biogen, Celgene, Lundbeck, Merck Serono, Novartis, Roche, Sanofi-Genzyme, Teva. Antonella Conte received speaking honoraria from Roche, Biogen, Novartis, BMS, Allmiral, Merck, Lundbeck and research support from Biogen. Paolo Gallo has been a consultant and member of Advisory Board for Bayer Schering, Biogen Italy, Genzyme, Merck-Serono, Almirall, Roche and Novartis Farma; has received funding for travel and speaker honoraria from Merck-Serono, Biogen Idec, Sanofi-Aventis, Novartis-Pharma, Teva, Roche, Almirall and Bayer-Schering Pharma; has received research support from Bayer, Biogen Italy, Merk-Serono, Genzyme, Roche, Novartis and Teva. Alessandra Lugaresi has served as an Amgen\/Horizon, Biogen, Bristol Myers Squibb\/Celgene, Merck Serono, Novartis, Roche, Sanofi\/Genzyme Advisory Board Member. She received congress and travel\/accommodation expense compensations or speaker honoraria from Alexion, Biogen, Merck Serono, Novartis, Roche, Sanofi\/Genzyme, and Fondazione Italiana Sclerosi Multipla (FISM). Her institutions received research grants from Novartis, Roche and Sanofi\/Genzyme. Francesco Patti received compensation for participation in advisory boards and speaker honoraria from Alexion, Almirall, Amgen, Biogen, Bristol Meyers and Squibb, Janssen, Merch, Novartis, Roche, Sanofi, Sandoz; received reserach grants from Biogen, Sanofi, Ministero della Ricerca, Ministero della Salute, and FISM; he is Associate Editor of Forntiers in Neurology, Frontiers in Immunology, and Neurology and Therapy. Maria Trojano has served on scientific advisory boards for Biogen, Novartis, Roche, the healthcare business of Merck KGaA, Darmstadt, Germany, Sandoz and Celgene (BMS); has received speaker honoraria from Biogen, Roche, Sanofi, the healthcare business of Merck KGaA, Darmstadt, Germany, Sandoz, Alexion and Novartis. Maria Pia Amato has received research grants from the National MS Society, Canadian MS Society, Italian Health Ministry, Regione Toscana, Bayer, Biogen, Merck, Novartis, Sanofi Genzyme, Teva, Almirall, Roche; and honoraria as a speaker and member of advisory boards from Bayer, Biogen, Merck, Novartis, Sanofi Genzyme, Teva, Almirall, Roche, Celgene BMS, Sandoz; she is member of the Editorial Board of the Multiple Sclerosis Journal. Massimo Filippi is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Neurological Sciences, and Radiology; received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi; speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}],"article-number":"428"}}